HLA-DR3, DR4 increase in chronic stage of Spanish oil disease

Effect of type-2 diabetes mellitus in long-term mortality in older adults: The NEDICES cohort study.

Diabetes research and clinical practice·2025

A phase I/II dose-escalation multi-center study to evaluate the safety of infusion of natural killer cells or memory T cells as adoptive therapy in coronavirus pneumonia and/or lymphopenia: RELEASE study protocol.

Trials·2021

Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE).

EClinicalMedicine·2021

SARS-CoV-2-Specific Memory T Lymphocytes From COVID-19 Convalescent Donors: Identification, Biobanking, and Large-Scale Production for Adoptive Cell Therapy.

Frontiers in cell and developmental biology·2021

Genomic sequences of five novel HLA class I alleles: A30:129, B08:195, B51:01:62, C01:147 and C*12:195:02.

HLA·2018

Genomic sequences of HLA-A68:169, HLA-B07:298 and HLA-B*39:129.

International journal of immunogenetics·2018

8 weeks versus 12 weeks of sofosbuvir-velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in India.

Lancet (London, England)·2026

Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.

Lancet (London, England)·2026

A trembling detour to the diagnosis of encephalitis: a neuroborreliosis case report.

Lancet (London, England)·2026

Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.

Lancet (London, England)·2026

Efficacy and safety of garetosmab, an activin A-blocking antibody, in fibrodysplasia ossificans progressiva (OPTIMA): a randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet (London, England)·2026

Radiotherapy versus observation following surgical resection of WHO grade 2 atypical meningioma (ROAM/EORTC-1308): an international, multicentre, open-label, phase 3, randomised controlled trial.

Lancet (London, England)·2026

Optimizing Mydriasis in Cataract Surgery: Efficacy and Safety of Intracameral Regimen vs Topical Cyclopentolate in RayOne EMV Implantation.

Medical science monitor : international medical journal of experimental and clinical research·2026

Restorative and regenerative therapies for vision loss.

Eye (London, England)·2026

[Magnetic resonance imaging of the orbital cavity: indications and diagnostic possibilities].

Klinische Monatsblatter fur Augenheilkunde·2026

Time-Dependent Efficacy of Hyperbaric Oxygen Therapy in Central Retinal Artery Occlusion.

Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc·2026

Visual Deficits in Diabetic Retinal Disease.

Ophthalmic epidemiology·2026

Challenges in glaucoma diagnosis in small optic discs: An OCT-based analysis.

Medicine·2026

Related Experiment Videos

HLA-DR3, DR4 increase in chronic stage of Spanish oil disease

Related Concept Videos

Effect of type-2 diabetes mellitus in long-term mortality in older adults: The NEDICES cohort study.

A phase I/II dose-escalation multi-center study to evaluate the safety of infusion of natural killer cells or memory T cells as adoptive therapy in coronavirus pneumonia and/or lymphopenia: RELEASE study protocol.

Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE).

SARS-CoV-2-Specific Memory T Lymphocytes From COVID-19 Convalescent Donors: Identification, Biobanking, and Large-Scale Production for Adoptive Cell Therapy.

Genomic sequences of five novel HLA class I alleles: A30:129, B08:195, B51:01:62, C01:147 and C*12:195:02.

Genomic sequences of HLA-A68:169, HLA-B07:298 and HLA-B*39:129.

8 weeks versus 12 weeks of sofosbuvir-velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in India.

Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.

A trembling detour to the diagnosis of encephalitis: a neuroborreliosis case report.

Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.

Efficacy and safety of garetosmab, an activin A-blocking antibody, in fibrodysplasia ossificans progressiva (OPTIMA): a randomised, double-blind, placebo-controlled, phase 3 trial.

Radiotherapy versus observation following surgical resection of WHO grade 2 atypical meningioma (ROAM/EORTC-1308): an international, multicentre, open-label, phase 3, randomised controlled trial.

Optimizing Mydriasis in Cataract Surgery: Efficacy and Safety of Intracameral Regimen vs Topical Cyclopentolate in RayOne EMV Implantation.

Restorative and regenerative therapies for vision loss.

[Magnetic resonance imaging of the orbital cavity: indications and diagnostic possibilities].

Time-Dependent Efficacy of Hyperbaric Oxygen Therapy in Central Retinal Artery Occlusion.

Visual Deficits in Diabetic Retinal Disease.

Challenges in glaucoma diagnosis in small optic discs: An OCT-based analysis.

Related Experiment Videos

HLA-DR3, DR4 increase in chronic stage of Spanish oil disease

Related Concept Videos

Related Articles